Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168655 · ClinicalTrials.gov registry record
Mavacamten in Obstructive Hypertrophic Cardiomyopathy
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 163
- Enrollment target
NCT07168655: Completed study, sponsored by Bristol-Myers Squibb.
NCT07168655 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 163 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07168655 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 163 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US
Interventions
- DRUG Mavacamten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2025-03-25 |
What the finished NCT07168655 record still lists
NCT07168655 is an observational study that tracks outcomes without assigning an intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Mavacamten is the first listed.
NCT07168655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07168655 about?
NCT07168655 is a clinical study titled "Mavacamten in Obstructive Hypertrophic Cardiomyopathy". The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US
What is the current status of trial NCT07168655?
This trial is currently completed. The enrollment target is 163 participants. The study started on 2023-02-21. Estimated completion is 2025-03-25.
What interventions are being tested in trial NCT07168655?
The interventions under investigation include: Mavacamten (DRUG).
Who is sponsoring clinical trial NCT07168655?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI